welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Jacques P. Tremblay, PhD
Department of Molecular Medicine
Faculty of Medicine, Université Laval
2705, Boulevard Laurier
Dr. Tremblay’s laboratory is renowned for his work on the transplantation of normal allogeneic myoblasts as a treatment for DMD. His Phase I clinical trial for this therapy showed that this transplant restores the expression of this protein in the patient’s muscle fibers.
In 2006, Dr. Tremblay received the Henry Friesen Award from the Royal College of Physicians and Surgeons of Canada for his work on the DMD therapy. His group is currently conducting a Phase I / II clinical trial on this therapy. In addition, his group is currently using CRISPR / Cas9 technology to correct the dystrophin gene, creating an additional deletion to produce a hybrid exon of the dystrophy gene, which not only restores the expression of dystrophin but also produces dystrophin with a normal structure.
Jacques P. Tremblay received a BSc in Biochemistry from McGill University in 1970, and a PhD in Neuroscience from UCSD (University of California in San Diego) in 1974. From 1975 to 1976, he was a postdoctoral fellow at the Laboratory of Neurobiology of l’Hôpital de l’Enfant-Jésus. Subsequently, he spent his entire career at Laval University.
A Breakthrough in Duchenne Muscular Dystrophy Offers Hope to Families with DuchenneDuchenne Muscular Dystrophy (DMD or Duch...
Michael A. Rudnicki, PhDDr. Michael Rudnicki is a Senior Scienti...
Stem Cell Therapy in Duchenne Muscular DystrophyThe purpose of this study was to study t...
Bespoke Is Often Better: How Scientists Are Customizing Gene TherapyWhen it comes to products from suits to ...
U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editingA U.S. appeals court on Monday allowed a...
Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (D...This research study is designed to evalu...
NCATS, FDA Co-Host Workshop on Gene Therapy for Rare Diseases“We are now at the point of translatin...